Department of Surgery, University of Virginia Health System, School of Medicine, Charlottesville, Virginia 22908, USA.
Ann Thorac Surg. 2011 Sep;92(3):880-8; discussion 888. doi: 10.1016/j.athoracsur.2011.04.105.
Small prosthesis size has been associated with poorer postoperative outcomes in aortic valve replacement (AVR). We hypothesized that the use of small aortic valve (AV) prostheses does not independently increase operative mortality following AVR, but that mortality may instead be related to comorbidities.
We examined the mortality among 4,621 patients who underwent primary AVR operations at 13 different statewide centers from 2003 to 2008. Patients were stratified by prosthesis size into groups with small (≤21 mm, n=1,810) and standard AV prostheses (≥23 mm, n=2,811). The effect of prosthesis size on outcomes was evaluated with univariate and multivariable regression analyses.
Operative mortality among patients undergoing primary AVR operations was 3.7%. Among isolated operations, small AV prostheses were implanted in more females (79.9% vs 21.0%, p<0.001) and older patients (68.9±12.3 years vs 63.8±13.9 years, p<0.001) than were standard-size AV prostheses, and carried a higher predicted risk of mortality according to the Society of Thoracic Surgeons Predicted Risk of Mortality Score (3.1 [interquartile range, 3.0] versus 2.2 [2.0], p<0.001) than did standard-size AV prostheses. Small AV prostheses incurred more major complications (19.5% vs 15.7%, p=0.01), a greater mortality (3.9% vs 2.3%, p=0.03), a longer postoperative length of stay (6.0 [3.0] vs 5.0 [3.0] days, p<0.001), and higher total costs ($29,738 [18,196] vs $26,679 [14,890], p<0.001) than did standard AV prostheses. However, when analyzed with multivariate regression, small AV prosthesis size and female gender were not independent predictors of operative mortality, whereas advanced age, cardiopulmonary bypass time, and aortic annular enlargement were important predictors of operative mortality.
Small aortic valve prosthesis size does not independently increase operative mortality following primary AVR. Increased morbidity and mortality among patients undergoing the implantation of small AV prostheses is related to the confounding effects of preoperative and operative risk factors. Annular enlargement may not always reduce mortality.
在主动脉瓣置换术(AVR)中,较小的假体尺寸与术后结果较差相关。我们假设使用小主动脉瓣(AV)假体不会独立增加 AVR 后的手术死亡率,但死亡率可能与合并症有关。
我们检查了 2003 年至 2008 年间在 13 个全州中心进行的 4621 例初次 AVR 手术患者的死亡率。根据假体尺寸将患者分为小尺寸(≤21mm,n=1810)和标准 AV 假体(≥23mm,n=2811)组。使用单变量和多变量回归分析评估假体尺寸对结果的影响。
初次 AVR 手术患者的手术死亡率为 3.7%。在单纯手术中,小 AV 假体在女性(79.9%对 21.0%,p<0.001)和年龄较大的患者(68.9±12.3 岁对 63.8±13.9 岁,p<0.001)中比标准尺寸 AV 假体更常用,并且根据胸外科医生预测死亡率评分(3.1[四分位距,3.0]对 2.2[2.0],p<0.001),其死亡率预测风险更高。小 AV 假体发生重大并发症的比例更高(19.5%对 15.7%,p=0.01),死亡率更高(3.9%对 2.3%,p=0.03),术后住院时间更长(6.0[3.0]对 5.0[3.0]天,p<0.001),总费用更高(29738 美元[18196]对 26679 美元[14890],p<0.001)。然而,通过多变量回归分析,小 AV 假体尺寸和女性并非手术死亡率的独立预测因素,而高龄、体外循环时间和主动脉瓣环扩大是手术死亡率的重要预测因素。
在初次 AVR 后,小主动脉瓣假体尺寸不会独立增加手术死亡率。植入小 AV 假体的患者发病率和死亡率增加与术前和手术风险因素的混杂效应有关。瓣环扩大不一定会降低死亡率。